Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Status:
Completed

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

This study will further investigate the safety and efficacy of nilotinib in newly diagnosed chronic myeloid leukemia patients in the chronic phase

Phase 3

Novartis Pharmaceuticals